Johanna Bendell, MD of Sarah Cannon Research Institute discusses the phase 3 study in advanced gastric or GE junction cancer patients that was presented at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Advertisement
Advertisement